Halozyme Therapeutics has signed a global partnership and licence agreement with Incyte to assess additional subcutaneous formulations of INCA033989 in patients with mutCALR-expressing MPNs.

The JCA process does not have any influence over pricing and Ipsen must still navigate reimbursement access on a country-by-country basis. Credit: HJBC / Shutterstock.com. The first published joint ...

The therapies’ availability will offer a route to personalised, mutation-specific approaches for types of rare blood cancers.

Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn).

UK biotech financing recovery was present in the private markets in Q2 2026 as the sector contends with a tough global funding landscape.

Aptar Pharma has launched a collaborative system-level framework designed to support the development of injectable drug delivery systems.